Poster Abstracts • OFID 2018:5 (Suppl 1) • S319 Methods. A retrospective review was conducted on 400 randomly selected patients with SAB, 200 pre-and 200 post-implementation of a four-part management checklist. The primary outcome was overall adherence to the checklist, which included: repeat blood cultures, echocardiography, correct antibiotic/route selection, and appropriate antibiotic duration. Secondary outcomes included adherence when an ID physician was not consulted, adherence to the four components individually, and appropriate imaging.
Conclusion. COMBO reduced the likelihood of PB but had a higher AKI rate. There were no significant differences in PB by BL class. Clinically, COMBO may reduce PB rates and prevent overuse of salvage antibiotic therapy. BL choice for COMBO warrants further investigation.
Disclosures. All authors: No reported disclosures. Methods. This was a retrospective cohort study of patients hospitalized at Veterans Affairs (VA) medical centers with MSSA bacteremia from January 1, 2002 to October 1, 2015. Patients were included if they were treated exclusively with nafcillin, oxacillin, cefazolin, or piperacillin/tazobactam (i.e., monotherapy with no changes in therapy). The primary outcome was 30-day mortality, and secondary outcomes were time to discharge, inpatient mortality, 30-day readmission, and 30-day S. aureus reinfection. Hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using unadjusted, quintile adjusted, and propensity-score (PS) matched (nearest neighbor, 0.05 caliper) Cox proportional hazards regression.
Comparative Effectiveness of Nafcillin or
Results. A total of 326 patients were included in the final analysis. When comparing nafcillin (n = 75)/oxacillin (n = 30) with cefazolin (n = 108), 30-day mortality was similar between groups (PS matched n = 40, HR 4.0, 95% CI 0.45-35.79), as were rates of the other outcomes assessed. When combining nafcillin/oxacillin with cefazolin, and comparing to piperacillin/tazobactam (n = 113), 30-day mortality was significantly lower in the nafcillin/oxacillin/cefazolin group (PS matched n = 66, HR 0.29, 95% CI 0.09-0.87). Inpatient mortality and 30-day mortality were significantly lower with nafcillin/oxacillin/cefazolin in PS-adjusted analyses (HR 0.29, 95% CI 0.11-0.73 and HR 0.23, 95% CI 0.10-0.50, respectively).
Conclusion. In hospitalized patients with MSSA bacteremia, no difference in mortality was observed between nafcillin/oxacillin and cefazolin in patients that were exclusively treated with these monotherapies. However, higher mortality was observed with piperacillin/tazobactam as compared with nafcillin/oxacillin/cefazolin, suggesting that it may not be as effective as other monotherapies for MSSA bacteremia.
Disclosures Background. Anti-staphylococcal penicillins (ASPs) have been regarded as firstline in the treatment of serious MSSA bloodstream infections (BSI) with cefazolin considered an alternative. Recent studies have suggested that infection outcomes between cefazolin and ASPs may be similar. The objective of this study was to compare the clinical efficacy and tolerability of cefazolin to ASPs for MSSA BSI.
Methods. A systematic review and meta-analysis was conducted. Articles were identified via PubMed, Web of Science, and the Cochrane Library. Studies written in English comparing cefazolin to ASPs for MSSA BSI in adult patients were included. Study quality was assessed using the Cochrane Risk of Bias Assessment Tool and the Newcastle-Ottawa Scale for prospective and retrospective studies, respectively. All review stages were independently conducted by two reviewers, with a third reviewer adjudicating any discrepancies. The fixed-or random-effects model was utilized, as appropriate. A planned subgroup analysis was conducted between high (>15%) vs. low (<14.9%) mortality probability as defined by logit functions applied at the study level.
Results. Nine studies were identified. Pooled data extracted from 1,726 cefazolin-and 2,716 ASP-patients indicated that cefazolin was associated with a significant reduction in treatment failure (OR: 0.70; 95% CI: 0.61-0.82; P < 0.001; I 2 = 14%) and crude, all-cause mortality (OR: 0.69; 95% CI: 0.59-0.81; P < 0.001; I 2 = 18%) compared with ASPs. Within a subset of studies (n = 6) demonstrating low mortality probability (<14.9%), cefazolin therapy remained protective against failure (OR: 0.70; P < 0.001; I 2 = 39%) and mortality (OR: 0.70; P < 0.001; I 2 = 35%). Within the high mortality probability (>15%) subset, no significant differences for failure or mortality were noted. The risk of adverse events was higher with ASPs (OR: 2.58; 95% CI: 1.00-6.64; P = 0.05).
Conclusion. Cefazolin was associated with significantly lower rates of failure, mortality, and treatment-related adverse events when compared with ASPs among less severely ill patients. Prospective, randomized controlled trials are needed to establish the role of these agents in serious MSSA BSI. 
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